Search Thermo Fisher Scientific
On this page
Chemically defined formulations designed to increase monoclonal antibody (mAb) galactosylation
In the competitive landscape of biologics manufacturing, achieving consistent, high-quality protein glycosylation is critical for therapeutic efficacy and stability. However, fine-tuning galactosylation through conventional trial-and-error can lead to inefficiencies and resource drain. The Gibco GlycanMod Panel is designed to streamline this process, empowering you to optimize glycosylation profiles rapidly and effectively.
With the GlycanMod Panel, you can:
- Compare and optimize glycosylation with ease: Evaluate and compare multiple formulations in parallel to identify the ideal solution for enhancing monoclonal antibody (mAb) galactosylation, saving valuable time and resources.
- Fine-tune critical quality attributes: Pinpoint key factors influencing glycosylation patterns, empowering you to adjust and control your process to achieve the desired N-glycan profile for therapeutic proteins.
- Access diverse, ready-to-use formulations: The GlycanMod Panel includes four distinct formulations, each designed to promote galactosylation while maintaining cell viability and productivity. These formulations are chemically defined, serum-free, and animal origin-free to enable high consistency and compliance with regulatory standards.
Designed for flexible integration
The GlycanMod Panel offers a solution for your galactosylation needs, helping you quickly modify protein quality while maintaining cell growth and productivity. This panel allows more control over glycosylation patterns, supporting consistent results across different processes, scales, and production environments.
Proven performance across CHO cell lines
GlycanMod Panel formulations have been shown to increase galactosylation across different CHO cell lines and processes, including batch and fed-batch systems. Evaluations demonstrate that these formulations enhance galactosylation while sustaining viable cell density (VCD) and antibody production.
Modifying galactosylation profiles across different media
The performance of GlycanMod Panel formulations in different chemically defined media and feeds was assessed using a CHO-K1 cell line in an Ambr 15 reactor. Each formulation was added at 0.4% on day 0, and antibody production and N-glycan profiles were measured on day 14 (Figure 1).
Figure 1. Effectiveness of GlycanMod Panel formulations across two different media as measured by the total galactosylation (G1F + G2F) percentage. Each formulation was added at 0.4% on day 0, and N-glycan profiles were measured on day 14. The addition of GlycanMod Panel formulations increased total galactosylation in CHO-K1 cells to varying degrees depending on the medium and/or feed. Notably, titers were not affected by the addition of the GlycanMod Panel formulations.
Comprehensive technical support
Our experienced scientific team can provide technical support throughout the evaluation process, including process consultation, data analysis, and detailed summary reports. This helps streamline optimization and facilitates smoother transitions into cGMP manufacturing.
Unlock the potential of the GlycanMod Panel
Take advantage of the GlycanMod Panel to help drive faster bioproduction timelines, help improve product quality and enable accelerated delivery to patients. Contact us to learn how our glycosylation solutions can enhance your workflow and maximize your therapeutic potential.
Additional bioprocessing resources
As a trusted partner, we are committed to supporting your journey toward innovative biotech solutions.
